CEL-SCI Corp CVM
CEL-SCI Corp (NYSE: CVM) is an oncology drug developer. Its lead program, Multikine (Leukocyte Interleukin, Injection), is in Phase 3 for newly diagnosed resectable locally advanced primary squamous cell carcinoma of the head and neck (no lymph node involvement, low PD-L1). Its next catalyst on record is Multikine: Start of 212-patient confirmatory registration study, contingent on raising capital; full enrollment 18-24 months after start (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Multikine — Start of 212-patient confirmatory registration study, contingent on raising capital; full enrollment 18-24 months after start (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Multikine | head and neck cancer (completed Phase 3; 212-patient confirmatory registration study planned, not yet started) | biologic-other | Phase 3 |
| L.E.A.P.S. product candidates | rheumatoid arthritis | biologic-other | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.